Nebuliumab, a monoclonal antibody that can relieve the suppression of immune response mediated by the PD-1 pathway and restore tumor-specific T-cell immunity, has been approved in various countries for first- and third-line treatment of unresectable/metastatic GC [105]. The gene discussed is PDCD1; the disease is neoplasm.